Q; Ceftaroline fosamil is relatively a new cephalosporin antibiotic. It targets which resistant bacteria? 


Answer: Methicillin-resistant Staphylococcus aureus (MRSA)

Ceftaroline is relatively a new cephalosporin with particular target activity against MRSA, ansd is recommended for use in complicated skin and skin structure infections. Also, it can be used in community-acquired bacterial pneumonia. It continue to retain the broad-spectrum activity against Gram-negative bacteria.

Clinically, it has unique advantage of synergism with Daptomycin in complicated MRSA infection of skin and deep tissue structures.


References:

1. R, Corey; Wilcox M; Talbot GH; et al. CANVAS-1: Randomized, Double-blinded, Phase 3 Study (P903-06) of the Efficacy and Safety of Ceftaroline vs. Vancomycin plus Aztreonam in Complicated Skin and Skin Structure Infections (cSSSI). 2008 Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Disease Society of America Conference.

2. Kanafani ZA, Corey GR (February 2009). "Ceftaroline: a cephalosporin with expanded Gram-positive activity". Future Microbiology. 4: 25–33.

3.  Parish D, Scheinfeld N (February 2008). "Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection". Current Opinion in Investigational Drugs (London, England : 2000). 9 (2): 201–9 

4. "Forest Announces FDA Approval of Teflaro(TM) (ceftaroline fosamil) for the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection" (Press release). Forest Laboratories. 2010-10-29. Retrieved October 30, 2010. 

5. Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, Rybak MJ, Kullar R, Dhand A, Rose WE, Goff DA, Bressler AM, Lee Y, Pogliano J, Johns S, Kaatz GW, Ebright JR, Nizet V - Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. - Clin Ther. 2014 Oct 1;36(10):1317-33.